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New malignancies after squamous cell carcinoma
and melanomas: a population-based study from
Norway
Trude E Robsahm1*, Margaret R Karagas2, Judy R Rees2 and Astri Syse3

Abstract
Background: Skin cancer survivors experience an increased risk for subsequent malignancies but the associated risk
factors are poorly understood. This study examined the risk of a new primary cancer following an initial skin cancer
and assessed risk factors associated with second primary cancers.
Methods: All invasive cutaneous malignant melanomas (CMM, N = 28 069) and squamous cell carcinomas (SCC,
N = 24 620) diagnosed in Norway during 1955–2008 were included. Rates of new primary cancers in skin cancer
survivors were compared to rates of primary malignancies in the general population using standardized incidence
ratios (SIR). Discrete-time logistic regression models were applied to individual-level data to estimate cancer risk among
those with and without a prior skin cancer, accounting for residential region, education, income, parenthood, marital
status and parental cancer status, using a 20% random sample of the entire Norwegian population as reference. Further
analyses of the skin cancer cohort were undertaken to determine risk factors related to subsequent cancers.
Results: During follow-up, 9608 new primary cancers occurred after an initial skin cancer. SIR analyses showed 50%
and 90% increased risks for any cancer after CMM and SCC, respectively (p < 0.01). The logistic regression model
suggested even stronger increase after SCC (130%). The highest risk was seen for subsequent skin cancers, but several
non-skin cancers were also diagnosed in excess: oral, lung, colon, breast, prostate, thyroid, leukemia, lymphoma and
central nervous system. Factors that were associated with increased risk of subsequent cancers include male sex, older
age, lower residential latitude, being married and low education and income. Parental cancer did not increase the risk
of a subsequent cancer after SCC, but was a significant predictor among younger CMM survivors.
Conclusions: Our results provide information on shared environmental and genetic risk factors for first and later
cancers and may help to identify individuals at high risk for subsequent cancers, which will be important as skin cancer
incidence continues to rise.
Keywords: Malignant Melanoma, Squamous Cell Carcinoma, Second cancer, Population-based, Sociodemographic
factors, Family

Background
Cutaneous squamous cell carcinoma (SCC) and malignant melanoma (CMM) are among the most prevalent
[1] and rapidly increasing malignancies in white populations worldwide [2]. In Norway, the incidence of these
cancers has increased sevenfold during the last fifty
years. In 2010, SCC and CMM represented more than
10% of all new cancer cases in Norway [3]. The major
* Correspondence: trude.eid.robsahm@kreftregisteret.no
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environmental risk factor for all skin cancers is ultraviolet radiation (UVR) from sunlight; consequently, there is
a distinct north–south gradient in skin cancer risk [4].
The type of UVR exposure (e.g. intermittent versus accumulated) appears to differ for SCC and CMM [5]. In
addition, individual characteristics such as skin type, eye
and hair color, nevi and immune suppression are important predictors of individual susceptibility to skin
cancer [6,7]. High socioeconomic status is also associated with CMM [8].
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SCC is a highly curable disease, and the most recent
five-year relative survival rates in Norway are 89% and
93% for men and women respectively [3]. Although
CMM carries a higher mortality rate, the 5-year survival
rate is still high (77% and 89% for men and women, respectively) [3], due to early diagnosis and successful
treatment. During the last fifteen years, several studies
have suggested that a history of skin cancer increases
the risk for a new primary cancer, both of the skin and
other sites [9-30]. Many of these studies were based on
cancer registry data, with high quality case ascertainment but lacking data on individual risk factors that
might explain this. Other studies have benefitted from
individual exposure data collected using questionnaires,
but these tended to be smaller and have less rigorous
confirmation of skin and subsequent cancers. A reduced
risk of new malignancies after skin cancer has also been
reported for some cancer sites [31-37], which some
argue is due to the potentially protective effect of high
levels of vitamin D that result from UVR exposure [38].
From the Nordic countries, Sweden, Finland and
Denmark have reported their risks of second cancers
after skin cancer [12-14,18,28,29], whereas Norway has
not previously reported on these risks. Therefore, we
used the Norwegian Cancer Registry data to describe the
risk of a new primary cancer following SCC or CMM,
and to further assess whether sociodemographic factors
or cancer family history were associated with risk of subsequent cancers after skin cancer. Identifying those at
greatest risk for subsequent cancers may benefit future
public health initiatives by targeting interventions appropriately in the prevention and/or early detection of subsequent malignancies.

Methods
Study population

Our study cohort included all persons with a histologically verified invasive cutaneous malignant melanoma
(N = 28 069) or squamous cell carcinoma (N = 24 620)
diagnosed as a first primary cancer in the period 1955–
2008 (Table 1). The Cancer Registry of Norway has registered all cancer diagnoses nationwide from 1953 onwards
(not including basal cell carcinoma of skin). Mandatory
reporting from multiple independent sources ensures the
collection of complete and high quality data [39]. Available information includes date and type of primary skin
cancer diagnosis, stage, and anatomical location (head/
neck, trunk, arm, leg/foot or other sites) as well as similar
data on subsequent cancers. To distinguish new primary
cancers from recurrences, the Cancer Registry uses histological information and medical record review; if the histology reports are similar, at least four months must have
passed since the initial cancer diagnosis for a later case to
be defined as a new primary cancer and clinical records
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must be consistent with a new primary according to the
cancer registry standard [39].
The Norwegian Population Register, the Norwegian
Education Register and the Norwegian Directorate of
Taxes provided information for the cases as well as the
general population on individual level characteristics
such as date of birth, emigration and death, residential
region, attained educational level (1960, 1970, and yearly
from 1980 onwards), income (annual from 1966 onwards), parity, and marital status. The data were linked
through unique personal identification numbers assigned
to every individual residing in Norway from 1960 onwards. Permission to match the data was provided by
the National Data Inspectorate in Norway after ethical
review of this study by the Norwegian Board of Medical
Ethics.
For our study, we obtained individual-level data on all
residents during the period 1955–2008 (N = 5.3 million).
We used all skin cancer cases and a 20% random sample
of the entire population for comparison (N = 1.1 million).
Follow-up for skin cancer cases began on the date of diagnosis. For the general population, follow-up began either
at age 20 or age in 1955 if greater than 20 at that time.
Age and calendar period were included as time-varying
covariates, 20–39, 40–59 and ≥ 60 years and 1955–64,
1965–74, 1975–84, 1985–94, 1995–2004 and 2005 and
above, respectively. As the majority of Norwegians have
completed their education by age 25 and having children
by age 35 for the time period under consideration, we
used educational level and parental status at end of
follow-up in our models. For residential region, marital
status and income, we modeled status at the start of
follow-up. The average follow-up time was 10.1 years for
skin cancer survivors, and 30.6 years for the general
population.
We examined the associations between an initial skin
cancer and new primary cancers of the skin as well as
mouth/pharynx, lung, breast, prostate, thyroid, leukemia
and lymphomas, which are the sites with the most evidence of an association in earlier studies [10-12,14-16,19,
21,23,25-30]. Exploratory analyses were also undertaken
to examine the risk of second cancer at other common
sites.
We examined the risk of second cancers by age at
diagnosis because young age at onset of the initial cancer
may indicate a genetic predisposition. We examined
residence by latitude (South, Mid and North, as previously described [40]) because the association between
skin cancer and subsequent malignancies is hypothesized
to be strongest further from the equator [21]. To account for detection bias attributable to increased attention to cancer symptoms after a skin cancer diagnosis,
we also examined the short- and long-term risks of subsequent cancer after diagnosis of a primary skin cancer.
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Table 1 Descriptive features of the cohort of persons with a first primary cutaneous malignant melanoma (CMM) or
squamous cell carcinoma (SCC) at time of the primary skin cancer diagnosis
CMM

SCC

Women

%

Men

%

Women

%

Men

%

20-40

3249

21.5

1943

15.0

248

2.3

270

2.0

40-59

5435

35.9

4908

38.0

1201

11.0

1492

10.9

≥ 60

6452

42.6

6082

47.0

9474

86.7

11 935

87.1

Age (median)

55.6

Age at 1st diagnosis

57.4

75.4

73.2

Anatomical site
Head/neck

2148

14.2

2025

15.7

6560

60.0

8809

64.3

Trunk

4353

28.8

7044

54.4

1659

15.2

2071

15.1

Arm

2346

15.5

1188

9.2

1103

10.1

1281

9.4

Leg/foot

5633

37.2

1786

13.8

1060

9.7

737

5.4

Other sites

656

4.3

890

6.9

541

5.0

799

5.8

10 875

71.9

9270

71.7

7878

72.1

9537

69.6

Mid

2998

19.8

2525

19.5

2235

20.5

2877

21.0

North

1263

8.3

1138

8.8

810

7.4

1283

9.4

Residential region
South

Educational level
≤ Primary school

496

3.3

617

4.8

420

3.8

653

4.8

Secondary school

5199

34.4

3446

26.6

5678

52.0

5847

42.7

Some college

4545

30.0

3271

25.3

3106

28.4

3359

24.5

≥ College degree

4896

32.3

5599

43.3

1719

15.8

3830

28.0

Not married

6270

41.4

3515

27.2

6981

63.9

4641

33.9

Married

8866

58.6

9418

72.8

3942

36.1

9056

66.1

Marital status

Parental status
No children
Children

3875

25.6

2989

23.1

3855

35.3

4226

30.9

11 261

74.4

9944

76.9

7068

64.7

9471

69.1

Annual income
No or missing

6467

42.7

4118

31.8

8930

81.7

9523

69.5

$ 1-9999

2573

17.0

1639

12.7

801

7.3

1609

11.8

$ 10 000–19 999

1712

11.3

1283

9.9

320

3.0

567

4.1

$ 20 000–39 999

2326

15.4

2166

16.8

462

4.2

782

5.7

$ ≥ 40 000

2058

13.6

3727

28.8

410

3.8

1216

8.9

0.0-2.0

2551

16.9

3050

23.6

2642

24.2

3491

25.5

2.1-5.0

2938

19.4

3235

25.0

3019

27.6

3875

28.3

5.1-10.0

3044

20.1

2610

20.2

2658

24.3

3427

25.0

10.1-15.0

2261

14.9

1577

12.2

1398

12.8

1655

12.1

15.1-20.0

1720

11.4

1088

8.4

648

6.0

690

5.0

20.1-25.0

1109

7.3

615

4.8

289

2.6

313

2.3

≥ 25.1

1513

10.0

758

5.8

269

2.5

246

1.8

Duration of follow-up (years)

Total number

15 136

100

12 933

100

10 923

100

13 697

100

No subsequent cancer

13 078

86.4

10 995

85.0

9030

82.7

9978

72.9

Any subsequent cancer

2058

13.6

1938

15.0

1893

17.3

3719

27.1
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We obtained information on parental cancer diagnoses
for the skin cancer survivors who had identified parents
(i.e. were alive in 1960). Overall, we were able to link
60% of the skin cancer survivors with their mother and
55% with their father. In general, the linkage rate decreased with increasing age at diagnosis, and we thus
performed analyses stratified by year of birth (all, birth
year > 1930 and birth year > 1950).
Statistical analyses

Three types of analyses were conducted. First, we used
standardized incidence ratios (SIR) to compare rates of
subsequent malignancies in skin cancer survivors with
rates of first primary cancer in subgroups of the general
population of comparable age, sex and calendar time.
The person-years at risk and the observed number of
cancer cases were counted by sex within 5-year age
groups (20–24, …, 80–84, 85+), and 5-year calendar periods (1955–59, …, 2000–04), except for the last period
which ran from 2005–08. The expected number of cancer cases was calculated by multiplying the number of
person-years in each age group and calendar period in
the skin cancer cohort by the corresponding cancer rates
in the general Norwegian population. The 95% confidence
interval (CI) for the SIR was based on the assumption that
the observed number of cases was Poisson-distributed and
the expected number was non-stochastic. The analyses
were performed using Stata 12 [41].
Second, a discrete-time logistic regression model was
used to assess the importance of individual-level risk
factors for the risk of a new primary cancer after skin
cancer versus a first primary malignancy. Series of
twelve-month observations were created for each individual. Individuals were followed from start of follow-up
to a first primary malignancy (in a 20% random selection
of the general population) or a subsequent malignancy
(in skin cancer survivors). Individuals were followed to
2008, unless death, emigration or a malignancy occurred
before this time. The follow-up time was categorized as
0–2 years, 3–5 years, 6–10 years, 11–15 years, 16–
20 years, 21–25 years or more than 25 years. Categorizations of the covariates are shown in Table 2. Interaction
terms between a primary skin cancer diagnosis and the
various sociodemographic features were included to assess possible effect modification. Based on these results,
stratified analyses were undertaken on variables for
which effect modification appeared to be present.
Third, internal analyses were undertaken to examine
whether cancer-related and sociodemographic factors influence the risk of subsequent malignancies within the
cohort of skin cancer survivors. The analyses explored
the possible impact of the anatomic site of the primary
skin cancer and history of parental cancer. All the
discrete-time models were run using the PROC
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LOGISTIC procedure in SAS 9.2 [42]. Time to subsequent malignancies in men and women was explored
using Kaplan-Meier plots, separately for CMM (Figure 1A)
and SCC (Figure 1B) survivors, using Stata 12 [41]. The
statistical significance level was set at 5%.

Results
Overall, 3996 and 5612 subsequent cancers occurred, respectively, among CMM and SCC survivors during
follow-up. The characteristics of individuals diagnosed
with skin cancer are displayed in Table 1. CMM patients
were diagnosed at an earlier age, were better educated,
had higher incomes, were more frequently married and
had children than SCC patients.
Standard incidence ratios (SIR)

We found 50% and 90% increases in the risks of subsequent
cancer after an initial CMM and a SCC diagnosis, respectively (Tables 3, 4). The strongest risks were observed for
subsequent skin cancers, and in particular for skin cancers
of the same histology as the index cancer. Increased risks
were also observed for several non-skin cancers (thyroid,
breast, prostate, leukemia and lymphomas) after both types
of skin cancer. After CMM, a 30% increase in risk of central
nervous system (CNS) tumors was observed and in men
we observed a decreased risk of lung cancer. After SCC,
more than a threefold and a sixfold risk increase was observed for mouth/pharynx and salivary gland tumors respectively, as well as a nearly 50% risk increase for lung
cancer. Further, the risks of pancreatic and colon cancer
were significantly elevated in both sexes, but in women we
found a decreased risk of cancers of urinary organs.
Logistic regression models

As several cancer forms are associated with socioeconomic status, site-specific analyses controlling for sociodemographic and -economic risk factors were conducted.
Results were fairly similar to those observed in the SIR
analyses (Table 5), e.g., for the risk of breast cancer after
either CMM or SCC. However, the model resulted in
higher risk estimates for leukemia, lymphoma and colon
cancer after CMM or SCC and for cancers of urinary organs after SCC. For prostate cancer there was a lower estimate after CMM but higher after SCC.
Table 2 shows estimates from a fully saturated
discrete-time logistic regression model, comparing the
risk of a first cancer in the general population with that
of a second cancer in skin cancer survivors. Compared
to the general population, the cancer risk was approximately 50% and 130% higher after an initial CMM and
SCC, respectively. An increased cancer risk was associated with male sex, older age, lower residential latitude,
recent calendar time, primary education, low income
and being married.
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Table 2 Odds ratios (OR) and 95% confidence intervals (CI) from a fully saturated discrete-time logistic regression model,
comparing the risk of a first cancer in the general population with that of a second cancer in skin cancer survivors
CMM
Events/Pyr1

SCC
OR (95% CI)

Events/Pyr

OR (95% CI)

Primary skin cancer
No

143 978/31.0 mill

1.00 ref

144 179/31.0 mill

1.00 ref

Yes

3662/288 823

1.53 (1.48,1.59)

5612/175 641

2.30 (2.22,2.37)

Female

72 768/15.8 mill

1.00 ref

72 319/15.7 mill

1.00 ref

Male

75 206/15.4 mill

1.28 (1.26,1.29)

77 472/15.4 mill

1.31 (1.29,1.32)

Sex

Age2
20-40 years

6447/12.0 mill

1.00 ref

6509/12.0 mill

1.00 ref

40-59 years

30 795/10.6 mill

5.37 (5.22,5.52)

30 241/10.5 mill

5.28 (5.14,5.43)

≥ 60 years

110 732/8.6 mill

20.58 (20.04,21.14)

113 041/8.6 mill

20.34 (19.80,20.9)

Residential region3
North

21 277/6.0 mill

1.00 ref

21 323/6.0 mill

1.00 ref

Mid

34 586/7.2 mill

1.30 (1.27,1.32)

34878/7.2 mill

1.30 (1.28,1.32)

South

92 111/18.0 mill

1.33 (1.31,1.35)

93 590/17.9 mill

1.35 (1.33,1.37)

Calendar period2
< 1965

8477/4.3 mill

1.00 ref

8354/4.3 mill

1.00 ref

1965-1974

20 484/5.4 mill

2.54 (2.47,2.61)

20 867/5.4 mill

2.62 (2.56,2.6)

1975-1984

27 276/5.9 mill

3.63 (3.54,3.73)

27 573/5.9 mill

3.73 (3.63,3.83)

1985-1994

33 071/6.3 mill

4.28 (4.17,4.40)

33 817/6.3 mill

4.45 (4.34,4.57)

1995-2004

40 142/6.6 mill

5.33 (5.19,5.47)

40 241/6.6 mill

5.41 (5.27,5.56)

≥ 2005

18 524/2.7 mill

5.99 (5.82,6.17)

18 939/2.6 mill

6.22 (6.04,6.40)

≤ Primary school

15 926/1.9 mill

1.00 ref

16 141/1.9 mill

1.00 ref

Secondary school

67 042/11.8 mill

0.32 (0.31,0.33)

67 915/11.8 mill

0.32 (0.31,0.33)

Some college

35 646/7.0 mill

0.30 (0.29,0.31)

36 079/7.0 mill

0.30 (0.29,0.30)

≥ College degree

29 360/10.5 mill

0.30 (0.29,0.31)

29 656/10.4 mill

0.30 (0.30,0.31)

4

Educational level

Marital status3
Not married

47 085/15.7 mill

1.00 ref

47 881/15.7 mill

1.00 ref

Married

100 889/15.5 mill

1.25 (1.24,1.27)

101 910/15.4 mill

1.27 (1.25,1.28)

138 424/28.9 mill

1.00 ref

139 451/28.9 mill

1.00 ref

9550/2.3 mill

0.95 (0.93,0.97)

10 340/2.2 mill

0.96 (0.94,0.98)

Parental status4
No children
Children
Income (annual)3
$ 05

60 395/9.1 mill

1.00 ref

62 871/9.1 mill

1.00 ref

$ 80–9 999

40 528/10.7 mill

0.92 (0.90,0.93)

40 556/10.7 mill

0.91 (0.90,0.92)

$ 10 000–19 999

34 425/8.7 mill

0.80 (0.79,0.82)

34 394/8.7 mill

0.80 (0.78,0.80)

$ 20 000–39 999

11 582/2.6 mill

0.78 (0.77,0.80)

11 140/2.5 mill

0.76 (0.74,0.78)

$ ≥ 40 000

1044/153 034

0.82 (0.77,0.87)

830/122 013

0.78 (0.73,0.84)

1

Number of events (new cancers) per person-year during follow-up. 2Time-varying covariates (yearly). 3At start of follow-up. 4At end of follow-up. 5Includes also
those with missing income data.

In the comparison between CMM survivors and the
general population, interactions were observed for educational attainment, attained age and calendar period

(pinteraction < 0.01). In stratified analyses, the risk of a subsequent cancer was higher for CMM survivors with an education at college or university level (Odds ratio (OR) 1.65,
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A

0.00

Failure distribution function
0.25
0.50
0.75

1.00

Kaplan −Meier failure estimates after CMM

0

10

20
30
40
Years after a primary CMM diagnosis
Women

50

Men

B

0.00

Failure distribution function
0.25
0.50
0.75

1.00

Kaplan−Meier failure estimates after SCC

0

10

20
30
40
Years after a primary SCC diagnosis
Women

50

Men

Figure 1 Kaplan-Meier plots of the timing of a second malignancy for men and women after a primary diagnosis of cutaneous
malignant melanoma (A) and a primary diagnosis of cutaneous squamous cell carcinoma (B).

CI 1.57-1.74) than for those with a lower education (OR
1.34, CI 1.26-1.42). Similarly, a CMM diagnosis before the
age of 60 significantly increased the risk of a subsequent
cancer (OR 2.59, CI 2.41-2.79) compared to those older
than 60 years (OR 1.43, CI 1.37-1.50). The interaction term
between calendar year as a linear variable and CMM

diagnosis suggested an increase in risk with more recent
calendar time. However, splitting the sample at year 1990
did not identify appreciable differences (≤ 1990: OR 1.57,
CI 1.50-1.64 vs. > 1990: OR 1.64, CI 1.52-1.77).
For SCC survivors in comparison to the general population, interactions were found for parental status,
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Table 3 Standard incidence ratios (SIR) with 95% confidence intervals (CI) for a second malignancy by cancer site in
men and women with a history of cutaneous malignant melanoma (CMM), adjusted for age and calendar period
Women (N = 15 1841)
2

3

Men (N = 12 9721)
3

ICD-10

Cancer site

O

SIR (95% CI)

O

SIR (95% CI)

C00-14

Mouth, pharynx

14

0.77 (0.46,1.30)

33

1.11 (0.79,1.56)

C18

Colon

163

1.02 (0.88,1.19)

134

1.16 (0.98,1.37)

C19-21

Rectum

57

0.87 (0.67,1.13)

62

0.93 (0.72,1.19)

C25

Pancreas

46

1.00 (0.76,1.33)

39

1.06 (0.77,1.45)

C33,34,38

Lung

109

1.12 (0.93,1.35)

119

0.72 (0.60,0.87)

C50

Breast

377

1.24 (1.12,1.37)

-

-

C50-58

Female organs

588

1.18 (1.09,1.28)

-

-

C61

Prostate

-

-

445

1.26 (1.15,1.38)

C64-68

Urinary organs

68

0.93 (0.73,1.18)

139

0.99 (0.84,1.17)

C70-72

CNS4

70

1.39 (1.09,1.75)

41

1.31 (0.98,1.78)

C73

Thyroid

19

1.27 (0.81,1.99)

13

2.78 (1.61,4.80)

C81-85

Lymphoma

56

1.29 (0.99,1.68)

60

1.56 (1.20,1.99)

C91-95

Leukemia

72

1.28 (1.01,1.60)

64

1.22 (0.87,1.43)

5

C00-96

Other sites

169

1.15 (0.99,1.34)

176

1.07 (0.92,1.24)

C43

CMM

438

7.59 (6.91,8.33)

411

9.44 (8.57,10.4)

C44

SCC

197

3.12 (2.71,3.59)

204

3.11 (2.71,3.56)

C00-96

All sites

2066

1.52 (1.46,1.59)

1943

1.49 (1.43,1.60)

C00-96

All, exc. skin

1431

1.16 (1.11,1.23)

1328

1.12 (1.06,1.18)

C00-967

All, exc. CMM

1628

1.26 (1.20,1.32)

1532

1.25 (1.19,1.31)

6

1

The number of cancer cases in the SIR-analyses differs slightly from that used in the logistic regression analyses as the data were extracted on different dates
from the Cancer Registry of Norway. 2The cancer sites are not mutually exclusive. 3Observed number of cases. 4Central nervous system tumors. 5Includes ICD-10
codes C15-17, C22-24, C26, C30-32, C37, C39-41, C45-49, C60, C62-63, C69, C74-76, C80, C88, C90. 6All sites except C43 and C44. 7All sites except C43.

educational attainment, attained age and calendar period
(pinteraction < 0.01). Risk for a subsequent cancer was
higher for SCC survivors with at least one child (OR
2.64, CI 2.48-2.80) compared to those without children
(OR 2.26, CI 2.15-2.37). Further, a higher risk of subsequent cancer was observed for SCC survivors with an
education at college or university level (OR 2.49, CI
2.38-2.62) compared to those with a lower education
(OR 1.97, CI 1.89-2.06). SCC diagnosis before the age
of 60 was associated with a higher risk of subsequent
cancer (OR 5.54, CI 4.88-6.29) compared to those
older than 60 years (OR 2.07, CI 2.00-2.15). Risk of
subsequent cancer was also higher after 1990 (OR
2.52, CI 2.42-2.62) than prior to this (OR 2.29, CI
2.15-2.42).

(data not shown). This was true for all cancer sites, skin
included.
Parental cancer

The risk for a new primary cancer after an initial CMM
was not associated with a history of cancer in their mother
(OR 1.05, CI 0.90-1.23), father (OR 0.95, CI 0.81-1.11) or
either parent (OR 1.00, CI 0.88-1.13), for individuals born
after 1930. When we restricted the analyses to those with
complete parental linkage (individuals born after 1950),
the respective estimates were elevated; risks of cancer after
CMM in individuals with a history of cancer in their
mother, father or either parent were 1.39 (CI 1.09-1.78),
1.38 (CI 1.09-1.76) and 1.52 (CI 1.21-1.92) respectively.
For SCC survivors, the estimates associated with parental
cancer were not significantly elevated in the overall or restricted analyses (data not shown).

Risk of subsequent cancer among skin cancer survivors

The results for the internal comparisons were quite
similar for the two subgroups of skin cancer survivors
and they confirmed the findings from the external analyses (Table 6). No clear difference in the overall risk of
subsequent cancer was found across the anatomical
sites of the primary skin cancer, after CMM or SCC

Time since first primary cancer

The risk of subsequent cancer after an initial skin cancer
increased with time and the risk excess was greater for
men than for women (Figures 1A and B). Whereas the
increase appeared almost linear for CMM survivors, it
rose in a non-linear manner for SCC survivors.
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Table 4 Standard incidence ratios (SIR) and 95% confidence intervals (CI) for a second malignancy by cancer site in
men and women with a history of cutaneous squamous cell carcinoma (SCC), adjusted for age and calendar period
Women (N = 10 9651)
2

3

Men (N = 13 7481)
3

ICD-10

Cancer site

O

C00-144

Mouth, pharynx

38

C07-08

Salivary glands

11

6.69 (3.71,12.1)

17

6.19 (3.85,9.95)

C18

Colon

176

1.25 (1.08,1.45)

197

1.09 (0.95,1.25)

C19-21

Rectum

45

0.86 (0.64,1.14)

96

0.98 (0.80,1.20)

C25

Pancreas

45

1.03 (0.77,1.38)

82

1.39 (1.12,1.73)

C33,34,38

Lung

82

1.46 (1.17,1.81)

303

1.49 (1.32,1.66)

C50

Breast

204

1.15 (1.00,1.32)

-

-

C50-58

Female organs

320

1.11 (0.99,1.24)

-

-

C61

Prostate

-

-

650

1.14 (1.06,1.23)

C64-68

Urinary organs

42

0.69 (0.51,0.94)

222

1.08 (0.94,1.23)

C70-72

CNS5

17

0.65 (0.40,1.04)

32

1.10 (0.78,1.56)

C73

Thyroid

12

7.30 (4.15,12.8)

3

0.60 (0.19,1.85)

C81-85

Lymphoma

64

2.14 (1.67,2.74)

113

2.41 (2.00,2.90)

SIR (95% CI)

O

SIR (95% CI)

3.03 (2.20,4.16)

114

3.23 (2.69,3.87)

C91-95

Leukemia

65

1.33 (1.04,1.69)

150

1.70 (1.45,1.99)

C00-966

Other sites

183

1.13 (0.98,1.31)

371

1.37 (1.23,1.51)

C43

CMM

95

3.09 (2.52,3.78)

122

2.76 (2.31,3.29)

C44

SCC

715

9.88 (9.18,10,6)

1249

10.1 (9.51,10.6)

C00-96

All sites

1898

1.89 (1.81,1.98)

3725

1.91 (1.84,1.96)

C00-967

All, exc. skin

1088

1.22 (1.15,1.30)

2354

1.33 (1.28,1.39)

C00-968

All, exc. SCC

1183

1.23 (1.16,1.30)

2476

1.31 (1.25,1.36)

1

The number of cancer cases in the SIR-analyses differs slightly from that used in the logistic regression analyses as the data were extracted on different dates
from the Cancer Registry of Norway. 2The cancer sites are not mutually exclusive. 3Observed number of cases. 4Includes ICD-10 codes C00-06 and C09-14. 5Central
nervous system tumors. 6Includes ICD-10 codes C15-17, C22-24, C26, C30-32, C37, C39-41, C45-49, C60, C62-63, C69, C74-76, C80, C88, C90. 7All sites except C43
and C44. 8All sites except C44.

Discussion
The risk of a new primary cancer was higher after an initial skin cancer compared to the risk of a first primary
cancer in the general Norwegian population, using multiple approaches. The highest risk was found for a subsequent skin cancer, but several non-skin cancers were
also diagnosed in excess including oral, colon, lung,
breast, prostate, urinary organs, CNS, thyroid, leukemia
and lymphomas. Many of the associations we observed
have been reported previously, but we were able to account for a number of sociodemographic factors, and
show that the risks remained elevated. Among skin cancer survivors an elevated risk of subsequent cancer was
associated with male sex, older age, lower residential
latitude, primary education only, low income and being
married and the risk increased over the study period.
Having children was associated with a slightly decreased
cancer risk. Having a parent with a history of cancer increased the risk for a new primary cancer after CMM if
diagnosed before age 60.
Individual risk of skin cancer is determined by UVR and
host susceptibility [43]. These are the likely explanations

for the increased risk of skin and perhaps lip cancer after
a CMM or SCC diagnosis, but medical surveillance after
the diagnosis may also be important. However, the reasons
why individuals with a history of skin cancer have a higher
risk of non-cutaneous malignancies, than those without a
skin cancer history, are less obvious.
As in previous reports [9,10,14-16,18,19,21-23,25-30,36],
we also observed that a history of skin cancer increased
the risk of leukemia and lymphoma. Although the mechanism for such an association is not fully understood, several mechanisms have been suggested. First, UVR impairs
the immune system, both locally in the skin and systemically [44-46]. Moreover, immunodeficiency as a result of
the disease itself [27,47,48], genetic factors [44] or previous treatment with radiation or chemotherapy [49,50], are
all potentially shared risk factors.
We found a history of SCC to be related to an increased risk of lung and mouth/pharynx cancers which
is consistent with several previous observations [9,12,16,
19-21,23,24,26-30,51]. Although UVR has been suggested to play a role also for these cancer types, similar
relationships were not observed after CMM. The most
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Table 5 Odds ratios (OR) and 95% confidence intervals (CI) of subsequent cancer by cancer site for cohorts with a
primary cutaneous malignant melanoma (CMM) or cutaneous squamous cell carcinoma (SCC) relative to that of the
general population, adjusted for covariates shown in Table 21
CMM
2

3

SCC

ICD-10

Cancer site

Events

OR (95% CI)

Events

OR (95% CI)

C00-144

Oral cavity

2768

0.96 (0.68,1.34)

2876

2.70 (2.19,3.34)

C07-08

Salivary glands

257

0.62 (0.14,2.74)

291

8.89 (5.29,14.93)

C18

Colon

13 281

1.28 (1.12,1.46)

13 190

1.62 (1.43,1.82)

C19-21

Rectum

6696

1.15 (0.93,1.42)

6768

1.10 (0.91,1.33)

C25

Pancreas

4551

1.14 (0.89,1.45)

4590

1.56 (1.27,1.91)

C33,34,38

Lung

12 347

0.72 (0.62,0.84)

12 613

1.23 (1.09,1.36)

C50

Breast

17 275

1.21 (1.07,1.36)

16 956

1.16 (1.01,1.34)

C50-58

Female organs

29 775

1.11 (1.02,1.22)

29 349

1.08 (0.96,1.21)

C61

Prostate

17 398

1.17 (1.02,1.34)

17 797

1.28 (1.14,1.43)

C64-68

Urinary organs

10 607

1.00 (0.85,1.18)

10 787

1.18 (1.03,1.37)

C70-72

CNS5

4348

1.73 (1.39,2.15)

4149

1.07 (0.79,1.44)

C73

Thyroid

1437

1.75 (1.19,2.56)

1435

1.27 (0.75,2.16)

C81-85

Lymphoma

4672

1.42 (1.14,1.76)

4678

2.78 (2.33,3.32)

C91-95

Leukemia

6096

1.63 (1.33,1.99)

6162

2.15 (1.83,2.53)

21 969

1.27 (1.13,1.43)

22 373

1.67 (1.51,1.84)

6363

7.99 (7.19,8.88)

5827

3.45 (2.94,4.05)

6

C00-96

Other sites

C43

CMM

C44

SCC

5382

3.31 (2.86,3.82)

6906

14.4 (13.2,15.7)

C00-96

All sites

147 974

1.53 (1.48,1.59)

149 791

2.30 (2.22,2.37)

All, exc. skin

136 229

1.16 (1.11,1.21)

137 058

1.51 (1.46,1.57)

7

C00-96
1

The number of cancer cases in the SIR-analyses differs slightly from that used in the logistic regression analyses as the data were extracted on different dates
from the Cancer Registry of Norway. The number of cases are nevertheless quite similar (CMM: SIR 28 156 vs 28 069, events 4009 vs 3996 and SCC: SIR 24 713 vs
24 620, event 5623 vs 5612). 2The cancer sites are mutually exclusive. 3Observed number of events in a 20% general population sample and the cohort of skin
cancer survivors. 4Includes ICD-10 codes C00-06 and C09-14. 5Central nervous system tumors. 6Includes ICD-10 codes 150–152, 155, 156, 158–161, 164, 178, 179,
192, and 195–199. 7All sites except C43 and C44.

reasonable explanation for the increased risk of lung and
oral cancer in SCC survivors may be related to tobacco
use, which also has been suggested as a risk factor for
SCC [29,51]. Moreover, a primary SCC was associated
with an increased risk of cancer in urinary organs that also
might be related to tobacco. While we have no information on tobacco use, prior studies that were able to control
for tobacco use still observed an increased risk of lung
[20,30], oral and kidney cancers [30]. Thus, it is possible
that the relationship observed between SCC and cancers
of mouth/pharynx, lung, and urinary organs lies elsewhere.
The risk of thyroid cancer was significantly increased,
both after an initial CMM (both sexes) and SCC (women
only), also consistent with previous findings [11,21,
25-27,31]. Common risk factors such as genetic or environmental exposure have been suggested to explain this
association [25]. A cancer diagnosis may also increase
future health vigilance, which may result in increased
detection of new malignancies. Physical examination for
CMM includes lymph node palpation in the thyroid area
and we cannot exclude the possibility of such surveillance
bias. Unfortunately, our numbers were too small to enable

a detailed analysis of the development of thyroid cancer
with time from a primary skin cancer diagnosis.
With respect to the elevated risk of CNS tumors, we
cannot exclude the possibility that the second primary
cancer, reported by the clinicians as a CNS tumor, could
in some patients be a metastasis from the primary
CMM. As CMM but not SCC is likely to spread to the
brain, this may explain why no such association was observed between SCC and risk of CNS tumors.
In line with previous studies [10,15,21,25,27,33,34,52],
an initial skin cancer diagnosis was found to be associated with an increased risk of colon, breast and prostate
cancer. For breast cancer, the relationship was most pronounced after a primary diagnosis of CMM. Shared hormonal mechanisms for CMM and breast cancer have
been proposed, although the epidemiological evidence of
the role of hormones in melanoma etiology is inconsistent [52]. All these three cancer forms, as well as skin
cancer, are associated with high socioeconomic status,
and shared risk factors linked to socioeconomic status
may account for the positive relationship, including frequent screening activity [25,34]. For CMM survivors this
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Table 6 Odd ratios (OR) and 95% confidence intervals (CI) from a fully saturated discrete-time logistic regression
model examining the risk for a subsequent cancer diagnosis within the cohorts with a primary cutaneous malignant
melanoma (CMM) or squamous cell carcinoma (SCC)
CMM
1

SCC

Events/Pyr

OR (95% CI)

Events/Pyr

OR (95% CI)

Female

2058/173 679

1.00 ref

1893/81 108

1.00 ref

Male

1938/115 144

1.51 (1.41,1.63)

3719/94 533

1.90 (1.79,2.01)

Sex

Age2
< 40 years

80/31 862

1.00 ref

19/3020

1.00 ref

40-59 years

807/106 669

2.89 (2.29,3.65)

222//17 362

2.28 (1.42,3.66)

≥ 60 years

3109/147 183

6.67 (5.31,8.39)

5371/155 259

4.62 (2.93,7.29)

Residential region3
North

275/23 927

1.00 ref

419/15 325

1.00 ref

Mid

703/54 955

1.09 (0.95,1.26)

1124/37 786

1.09 (0.98,1.23)

3018/209 941

1.20 (1.06,1.36)

4069/122 530

1.20 (1.08,1.33)

South
Calendar period2
< 1965

6/2959

1.00 ref

35/4411

1.00 ref

1965-1974

71/13 448

3.01 (1.30,6.98)

168/10 542

2.51 (1.73,3.64)

1975-1984

276/34 380

4.92 (2.15,11.24)

438/22 580

3.61 (2.50,5.20)

1985-1994

913/69 763

7.80 (3.43,17.34)

1281/40 225

6.46 (4.52,9.24)

1995-2004

1707/112 983

8.88 (3.91,20.17)

2364/64 765

7.76 (5.44,11.1)

≥ 2004

1023/55 290

10.52 (4.63,23.9)

1326/33 118

8.73 (6.10,12.5)

63/5193

1.00 ref

178/6203

1.00 ref

4

Educational level
≤ Primary
Secondary

1285/85 407

0.80 (0.61,1.04)

2514/82 333

0.60 (0.50,0.71)

Some college

1293/85 733

0.79 (0.60,1.05)

1577/46 489

0.60 (0.50,0.72)

≥ College degree

1355/112 490

0.80 (0.61,1.05)

1343/40 616

0.61 (0.51,0.74)

Marital status3
Not married

1089/84 671

1.00 ref

2161/72 265

1.00 ref

Married

2907/204 152

1.02 (0.94,1.10)

3451/103 376

1.01 (0.95,1.08)

881/68 530

1.00 ref

1692/56 884

1.00 ref

3115/220 293

0.91 (0.84,0.99)

3920/118 757

0.93 (0.87,0.99)

Parental status4
No children
Children
Income (annual)3
$ 05

1586/81 524

1.00 ref

3982/113 773

1.00 ref

$ 80–9 999

679/57 594

0.83 (0.75,0.91)

715/24 518

0.85 (0.78,0.92)

$ 10 000–19 999

514/50 340

0.68 (0.61,0.75)

300/12 099

0.76 (0.67,0.85)

$ 20 000–39 999

713/57 131

0.75 (0.68,0.82)

334/13 692

0.65 (0.58,0.74)

$ ≥ 40 000

504/42 234

0.65 (0.58,0.73)

281/11 559

0.59 (0.51,0.67)

1

Number of events (new cancers) per person-year during follow-up. 2Time-varying covariates (yearly). 3At start of follow-up. 4At end of follow-up. 5Includes also
those with missing income data.

is somewhat confirmed by the lowering of the risk estimates for breast and prostate cancer once socioeconomic factors were taken into account. In contrast, for
SCC survivors, the risk estimates for these three cancers
rose when accounting for socioeconomic factors.

Sociodemographic factors

Several cancer diseases are strongly associated with socioeconomic resources [53] and socioeconomic factors
have been suggested to represent mediators by which
environmental risk factors vary within a population. In
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the present study we observed the highest cancer risk in
the lowest educational and income levels, and it is likely
that this may be attributed to shared adverse lifestyle
factors (i.e. smoking habits, alcohol intake, sun protection, diet). The Norwegian health care system intends to
ensure equal health care for all inhabitants, independent
of socioeconomic level. Nevertheless, individuals who
belong to a lower social class tend to have lower health
vigilance and participation in surveys and screening programs to minimize the burden of cancer [54,55]. Therefore, we cannot exclude the possibility that our results,
at least partly, might be influenced by such mechanisms.
The high risk observed in the elderly may be due to
changed sun exposure habits and increased outdoor activities after retirement [56], but there may also be an effect of an age-related diminished immune response
[57,58]. Analyses stratified by age, on the other hand,
showed that compared to persons in the general population, the risk of a second primary cancer was greatest for
the youngest skin cancer survivors, particularly for SCC
survivors. A possible explanation might be a genetic susceptibility to skin cancer, which is associated with young
age at diagnosis [59], and such susceptibility may also increase the risk for subsequent cancers. Further, the
stronger effect of young age seen for SCC survivors may
be due to the different patterns of UVR exposure associated with the two skin cancer types (intermittent/accumulated) and to behavior after diagnosis. A CMM diagnosis
may, because of its lethal potential, lead to a more sunprotective behavior compared to a SCC diagnosis.
Moreover, steep increases in skin cancer rates over
time has been suggested to reflect increased UVR doses
[56], and this may in part explain the observed increase
of subsequent cancers by calendar time.
The status of being married was associated with an increased risk of subsequent cancer after skin cancer, while
having children slightly decreased the risk. Having a
family influences the lifestyle in several ways, as they
may help ensure more optimal medical surveillance as
well as reinforce better health behaviors after diagnosis
(i.e. smoking habits, alcohol intake, sun protection, diet,
screening attendance) [60], which may cause these
relationships.

Time since first primary cancer

Parental cancer

Limitations and strengths

Young age at onset of the initial cancer may be an indication of a genetic predisposition [61]. Contrary to previously reported work [21,62,63], having a parent with
cancer did not generally increase the risk of being diagnosed with a subsequent malignancy. However, analyses
restricted to individuals born after 1950, showed a near
50% increase in risk when either parent had a history of
cancer. Disentangling the effect of age and parental cancer is, however, not possible due to data limitations.

The study has several obvious strengths including the
long time-span, covering more than 50 years of followup, and the large study population, covering the entire
Norwegian population. Several cancers were diagnosed
in excess, but the highest risk was found for a subsequent skin cancer, particularly of similar type. General
practitioners and dermatologists interacting with skin
cancer survivors should be aware of this in their surveillance and follow-up.

An increased health awareness or close follow-up by the
health care personnel may result in earlier diagnoses of
new cancers in CMM and SCC survivors compared to
that of the general cancer-free population [15,55].
Nevertheless, it is unlikely that this can fully explain the
observed elevated cancer risk. Higher risk was observed
in men than in women, and due to gender difference in
health vigilance, we would expect the opposite as
women more often interact with health care personnel
[64]. The nonlinear increase for SCC survivors may help
explain why the interaction terms between a skin cancer
diagnosis and calendar year were statistically significant
whereas the stratified analyses with a cut-point set arbitrarily in 1990 yielded overlapping confidence intervals
for CMM, but not for SCC.
Vitamin D

UVR promotes vitamin D synthesis and vitamin D is
demonstrated to regulate several genes involved in cancer processes and is hypothesized to inhibit cancer development [38]. Inverse relationships between a history
of skin cancer, as a proxy of high vitamin D levels, and
risk of subsequent cancers support this hypothesis
[31,32,34-37], but the vitamin D hypothesis is not supported by the large number of studies that report increased risks of second primary cancers after skin cancer
[9-30,33], and neither by the present results. We found
the highest risk of subsequent cancer in the South region, which has the highest UVR dose in Norway. Recently, a study including four cohorts from different
regions of Norway observed a slightly higher mean level
of serum vitamin D in the cohort comprising residents
from the southern part of the country [65]. Therefore,
low levels of vitamin D might not explain our findings,
although we cannot exclude the possibility that individuals with a history of skin cancer have insufficient vitamin D-levels due to changed sun-exposure habits after
diagnosis. Results from a Danish study, however, counters this hypothesis as it demonstrates that previous
CMM patients not are more cautious sun bathers [66].
We can also not exclude that other effects of UVR exposure, such as immunodeficiency, may play a role.
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Individual-level information on some potential confounding variables was available and was found to influence the risk estimates. Less adjusted models are thus
likely to over- or underestimate the real risk increase in
skin cancer survivors, depending on the direction of the
influence of excluded variables. A limitation of the study
is the lack of information on parental cancer in older
skin cancer survivors. Further, the use of a 20% sample
resulted in larger standard errors and thus wider confidence intervals than would have been obtained if we had
included the whole population. This is particularly relevant for the site-specific analyses of less common cancer
forms, but nevertheless unlikely to have impacted our
estimated significantly. Another limitation is the lack of
behavioral risk factors such as smoking habits, sun exposure habits, body mass index (BMI), physical activity
etc., which would have given more direct information on
behavioral changes that may minimize the risk for a second cancer. Lastly, as we chose to primarily focus on socioeconomic factors at time of diagnosis, we are unable
to account for changes in these over the life course.
Such analyses would shed light on the relevance of developments in socioeconomic characteristics that have
taken place in Norway as well as in other industrialized
countries over the last 50 years. Nonetheless, there is little reason to believe that the development has been
much different for skin cancer survivors compared to
the general population given that we adjusted for age,
calendar period and follow-up time.

Conclusions
Heightened public awareness may be important to prevent subsequent cancers in skin cancer survivors as the
skin cancer incidence rates continue to rise. Of particular relevance to general practitioners and dermatologists
dealing with skin cancer survivors, is the need for enhanced surveillance for a new skin cancer. Further, our
results provide information on shared risk factors for
first and later cancers that may help in identifying individuals at high risk for subsequent cancers, and for
whom particular attention ought to be directed.
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